Unusual Volume Noted in Monday's ETF: IHE
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 24 2025
0mins
Source: NASDAQ.COM
ETF Performance: The iShares U.S. Pharmaceuticals ETF saw significant trading volume on Monday, with Pfizer up 1.4% and Merck up 4%.
Top Performer: Nektar Therapeutics was the best-performing component of the ETF, increasing by 8.4% during the session.
Lagging Component: Organon was the only component trading lower, down by 2.7%.
Market Commentary: The views expressed in the article are those of the author and do not necessarily reflect Nasdaq, Inc.'s opinions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for OGN is 8.50 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 9.590
Low
5.00
Averages
8.50
High
12.00
Current: 9.590
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
